Looking forward, DexCom's management has reiterated its fiscal year 2025 forecast, anticipating revenue growth of 14% with a ...

Stock analysts at Leerink Partnrs increased their Q1 2025 earnings per share estimates for DexCom in a research report issued ...

DexCom , Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM) systems for diabetes management with a market capitalization of $34.8 billion, finds itself at a critical juncture as it ...

DexCom reported Q4 revenue of $1.11 billion, surpassing estimates. The company reaffirmed its 2025 outlook while analysts ...

DexCom specializes in continuous glucose monitoring systems, primarily focusing on individuals managing diabetes. Its innovative CGM systems, like the G6 and the newer G7, offer real-time glucose ...

DexCom projects 2025 revenue of $4.6 billion, representing 14% growth. This forecast assumes strong demand for CGM systems, expanded reimbursement coverage, and a second-half launch of a 15-day G7 ...

Reports Q4 revenue $1.11B, consensus $1.10B. “In 2024, we implemented our largest US commercial sales force expansion, had two major product ...

Kingsview Wealth Management LLC cut its stake in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 45.0% in the 4th quarter, according to the company in its most recent disclosure with the ...

Medical device maker Dexcom beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with diabetes.

Q4 2024 Earnings Call Transcript February 13, 2025 DexCom, Inc. misses on earnings expectations. Reported EPS is $0.45 EPS, expectations were $0.4792. Operator: Thank you for standing by. My name is ...